![]() |
市場調查報告書
商品編碼
1500219
重組細胞培養補充品市場:按產品、來源、應用和最終用途 - 2024-2030 年全球預測Recombinant Cell Culture Supplements Market by Product (Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors), Source (Animals, Human), Application, End-use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
重組細胞培養補充品市場規模預計 2023 年為 6.8877 億美元,2024 年達到 7.8431 億美元,預計 2030 年將達到 17.6346 億美元,複合年成長率為 14.37%。
重組細胞培養補充品是生物工程產品,旨在支持人工環境中細胞的生長、增殖和維持。這些補充品是透過重組 DNA 技術製造的,該技術將編碼特定蛋白質或生長因子的 DNA 插入宿主細胞,從而產生這些所需的生物元件。其作用是最佳化成功培養哺乳動物、細菌和酵母細胞所需的細胞培養條件,以用於各種應用,包括治療性蛋白質和疫苗的生產,以及在組織工程和再生醫學中的應用。重組細胞培養補充品市場的主要促進因素包括生物技術研究的進步、對生物製藥的需求不斷成長以及細胞培養方法在藥物開發中的使用增加。此外,慢性病的全球流行正在推動新型療法的市場開拓,進一步推動市場成長。儘管成長潛力巨大,重組細胞培養補充品市場仍面臨挑戰,特別是高製造成本和嚴格的監管要求。然而,再生醫學和組織工程領域的不斷擴大正在為重組細胞培養補充品市場創造重大機會。此外,幹細胞治療和基因工程研究的進步預計將為重組細胞培養補充品的應用開闢新途徑,並成為市場擴張的驅動力。
主要市場統計 | |
---|---|
基準年[2023] | 6.8877 億美元 |
預測年份 [2024] | 78431萬美元 |
預測年份 [2030] | 17.6346億美元 |
複合年成長率(%) | 14.37% |
區域洞察
由於其先進的生物技術研究環境和對生命科學的大量投資,美洲地區在重組細胞培養補充品市場呈現出強勁的成長模式。特別是,對再生醫學和細胞療法的日益重視增加了對高品質重組補充品的需求。此外,該地區是主要生物製藥公司和研究機構的所在地,提高了市場參與度和創新能力。 EMEA地區呈現多元化的市場表現,其特點是歐洲成長強勁,中東影響力逐漸增強,非洲穩步推進。歐洲市場受益於大量的研究資金、成熟的製藥業以及支持生物技術創新的法規環境。同時,在生命科學戰略投資的推動下,中東地區對生物製藥研究的興趣日益濃厚。儘管非洲在這一領域仍在發展,但由於對生物技術和醫療基礎設施的認知和投資的增加,它顯示出成長潛力。在中國、日本、韓國和印度等國家快速成長的生物技術產業的推動下,亞太地區預計將在重組細胞培養補充品市場中呈現最高的成長率。該地區受益於醫療基礎設施的改善、生物製藥研發投資的增加以及國內外生物技術公司的夥伴關係和合作的增加。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在重組細胞培養補充品市場中的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對重組細胞培養補充品市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對重組細胞培養補充品市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[188 Pages Report] The Recombinant Cell Culture Supplements Market size was estimated at USD 688.77 million in 2023 and expected to reach USD 784.31 million in 2024, at a CAGR 14.37% to reach USD 1,763.46 million by 2030.
Recombinant cell culture supplements are bioengineered products designed to support the growth, proliferation, and maintenance of cells in an artificial environment. These supplements are manufactured through recombinant DNA technology, which involves the insertion of DNA encoding specific proteins or growth factors into host cells, leading to the production of these desired biological elements. Their role is pivotal in optimizing the cell culture conditions necessary for the successful cultivation of mammalian, bacterial, or yeast cells for various applications, including the production of therapeutic proteins and vaccines and for use in tissue engineering and regenerative medicine. The primary drivers for the recombinant cell culture supplements market include advancements in biotechnology research, rising demand for biopharmaceuticals, and the increasing use of cell culture methods in drug development. Moreover, the rising prevalence of chronic diseases globally boosts the development of novel therapeutics, further propelling market growth. Despite the significant growth potential, the recombinant cell culture supplements market faces challenges, particularly in the form of high production costs and stringent regulatory requirements. However, the expanding field of regenerative medicine and tissue engineering presents considerable opportunities for the recombinant cell culture supplements market. Furthermore, the ongoing research in stem cell therapy and genetic engineering is expected to open new avenues for the application of recombinant cell culture supplements, thereby driving market expansion.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 688.77 million |
Estimated Year [2024] | USD 784.31 million |
Forecast Year [2030] | USD 1,763.46 million |
CAGR (%) | 14.37% |
Regional Insights
The Americas region exhibits a robust growth pattern in the recombinant cell culture supplement market owing to its advanced biotechnological research landscape and substantial investments in life sciences. The growing emphasis on regenerative medicine and cell-based therapies particularly propels the demand for high-quality, recombinant supplements. Moreover, the presence of major biopharmaceutical companies and research institutions in this region amplifies market engagement and innovation. The EMEA region displays a diverse market performance characterized by strong growth in Europe, gradually increasing influence in the Middle East and steady advancements in Africa. The European market benefits from significant research funding, a well-established pharmaceutical industry, and a regulatory environment that supports biotechnological innovations. Meanwhile, the Middle East is witnessing an emerging interest in biopharmaceutical research, fuelled by strategic investments in life sciences. Africa, though still developing in this sector, shows potential for growth with increasing awareness and investment in biotechnology and healthcare infrastructure. Asia-Pacific is projected to exhibit the highest growth rate in the recombinant cell culture supplements market, driven by rapidly growing biotech sectors in countries such as China, Japan, South Korea, and India. The region benefits from improvements in healthcare infrastructure, rising investments in biopharmaceutical R&D, and an increasing number of partnerships and collaborations involving local and international biotech firms.
Market Insights
The market dynamics represent an ever-changing landscape of the Recombinant Cell Culture Supplements Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Recombinant Cell Culture Supplements Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Recombinant Cell Culture Supplements Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
Nucleus Biologics collaborates with Core Biogenesis to revolutionize the availability of Good Manufacturing Practice (GMP) recombinant proteins for the industry. This partnership designates Nucleus Biologics as the GMP manufacturer and distributor of Core Biogenesis' plant-expressed recombinant human proteins, integrating these advanced proteins into Krakatoa pod-based media manufacturing systems by Nucleus Biologics and Stoic Bio. [Published On: 2024-01-24]
Albumedix and Heartseed announce Recombumin as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences
Albumedix Ltd and Heartseed Inc. announced a pivotal development in cardiac therapy. Their collaboration has enabled the first human dosing of HS-001, an experimental treatment by Heartseed for advanced heart failure, utilizing Recombumin, a non-animal derived recombinant albumin, as an essential excipient. This partnership underscores Albumedix's commitment to enabling advanced therapeutic innovations, demonstrated by the strategic use of Recombumin to enhance cell viability and support cardiomyocyte sphere formation in HS-001. [Published On: 2023-03-14]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Recombinant Cell Culture Supplements Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Recombinant Cell Culture Supplements Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Becton, Dickinson and Company, Bio-Techne Corporation, BPS Bioscience, Inc., Cell Sciences, Inc., Cytiva, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, HiMedia Laboratories Pvt Ltd, InVitria, Kerry Group PLC, Kingfisher Biotech, Inc., Laurus Labs Limited, Lonza Group Ltd., Merck KGaA, Novo Nordisk A/S, Novozymes A/S, PELOBIOTECH GmbH, Repligen Corporation, Sartorius AG, STEMCELL Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., and Zhuhai Gene-Biocon Biological Technology Co., Ltd..
Market Segmentation & Coverage